Skip to main content
. 2020 Feb 12;11(2):e00128. doi: 10.14309/ctg.0000000000000128

Figure 5.

Figure 5.

Treatment pathways in CD incident cohorts for (a) 2008–2011 and (b) 2012–2014. 5-ASA, 5-aminosalicylic acid; CD, Crohn's disease; IMM, immunomodulator; other Combo Bio, other combination with a biologic; other Combo Nonbio, other combination with a nonbiologic.